SWI swissinfo.ch recently highlighted Leman Biotech in research development of cancer immunotherapy in Switzerland. The article focuses on the innovative research conducted by Professor Li Tang, co-founder of Leman Biotech, and his research team, Laboratory of Biomaterials for Immunoengineering. The research aims at overcoming T-cell exhaustion and improving the efficacy of current immunotherapies. The article sheds light on Leman Biotech's cutting-edge approach and its potential to revolutionize cancer treatment.
T-cell exhaustion, a state of metabolic dysfunction where tumor-specific T cells are exhausted faster than they can regenerate, has been a significant hurdle in cancer treatment. Many current immunotherapeutic strategies focus on stimulating T cells to increase their activation status, but this approach leads to rapid exhaustion, similar to a sprint for a long-distance runner fueled by energy drinks.
In response to this challenge, Leman Biotech has developed a unique metabolically enhanced therapy that allows T cells to maintain a more balanced metabolic state, enabling them to endure the entire "marathon" of fighting cancer. Prof. Tang Li emphasized the five years of laboratory research conducted to validate the technology's feasibility and advanced concepts. The company has secured funding for clinical translation and aims to deliver positive outcomes for cancer patients, collaborating with partner companies to improve response rates, cure rates, and the safety of tumor immunotherapy.
SWI swissinfo.ch, an international online media outlet affiliated with the Swiss Radio and Television Group (SRG SSR), provides multimedia information in ten languages. With its global perspective, SWI swissinfo.ch offers independent and comprehensive coverage of political, economic, technological, cultural, and social events in Switzerland. The platform is dedicated to promoting cultural exchange, facilitating dialogue between different communities, and sharing diverse experiences and perspectives.
For the original news article, please refer to
https://www.swissinfo.ch/eng/business/swiss-cancer-research-could--boost--immunotherapy/48254512
